Differential EBI2 Expression Upon Allelic Status of the rs9557195 Polymorphism
试验速览
- 阶段
- 不适用
- 入组人数
- 340
- 试验地点
- 1
- 主要终点
- EBI2 expression - dependent on rs9557195 allele status (FACS)
研究概览
简要总结
EBI2 is a risk gene for inflammatory bowel diseases (rs9557195). Patients of the Swiss IBD cohort study have been genotyped for the allelic status of EBI2. The investigators will test the influence of rs9557195 genoty (TT or CC allel), inflammatory activity and current treatment (infliximab vs. vedolizumab) on expression and activity of EBI2 on blood lymphocytes, mRNA expression of EBI2 and UBAC2 (located on the opposite DNA strand of EBI2) and activity of lymphocytes on a migraton assay.
详细描述
EBI2 is a risk gene for inflammatory bowel diseases (rs9557195). EBI2 is a G protein coupled receptors expressed on the immune cells. EBI2 directs migration and activity of immune cells.
Patients of the Swiss IBD cohort study have been genotyped for the allelic status of EBI2. The investigators will recruit patients with Crohn's disease and ulcerative colitis, assess epidemiological and clinical parameters (including clinical activity of IBD) draw blood, isolate lymphocytes, DNA and RNA.
The investigators will test the influence of rs9557195 genotype (TT or CC allel), inflammatory activity and current treatment (infliximab vs. vedolizumab) on expression and activity of EBI2 on blood lymphocytes (by FACS using an EBI2-antibody), mRNA expression (by qPCR) of EBI2 and UBAC2 (located on the opposite DNA strand of EBI2) and activity of lymphocytes on a migration assay.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient with IBD OR healthy volunteer
- •No major uncontrolled medical/ surgical/ psychiatric condition requiring ongoing management besides IBD in the respective study groups. Well controlled conditions (i.e. medically controlled arterial hypertension, occupational asthma) may be present
排除标准
- 未提供
结局指标
主要结局
EBI2 expression - dependent on rs9557195 allele status (FACS)
时间窗: at time of inclusion into the study
EBI2 levels in PBMCs will be determined by FACS, and compared according to allele status of rs9557195
次要结局
- Motility of PBMCs dependent on rs9557195 allele status (Boyden chamber)(at time of inclusion into the study)
- EBI2 expression - dependent on rs9557195 allele status (RT-PCR)(at time of inclusion into the study)
- UBAC2 expression - dependent on rs9557195 allele status (RT-PCR)(at time of inclusion into the study)
- EBI2-expression (FACS) in individuals treated with infliximab vs. vedolizumab(at time of inclusion into the study)
- EBI2-expression (FACS) according to gut inflammation(at time of inclusion into the study)